ストックスクリーナーアプリを入手
13.15
0.98%
-0.13
アフターアワーズ：
13.35
0.20
+1.52%
前日終値:
$13.28
開ける：
$13.35
24時間の取引高:
197.84K
Relative Volume:
0.71
時価総額：
$431.32M
収益：
$65.42M
当期純損益:
$-32.96M
株価収益率:
-10.35
EPS:
-1.27
ネットキャッシュフロー:
$-19.87M
1週間 パフォーマンス:
-0.53%
1か月 パフォーマンス:
+12.49%
6か月 パフォーマンス:
+16.58%
1年 パフォーマンス:
+100.76%
1日の値動き範囲:
$12.87
$13.84
1週間の範囲:
$12.43
$13.91
52週間の値動き範囲:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
NPCE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.15 | 429.99M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
133.58 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
NeuroPace secures USD 75M in debt financing - Medical Buyer
BNP Paribas Financial Markets Acquires New Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NeuroPace Secures $75 Million Credit Facility with MidCap - TipRanks
NeuroPace Secures $75 Million Credit Facility From MidCap Financial - marketscreener.com
NeuroPace secures $75 million credit facility with MidCap Financial - Investing.com Australia
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Neuropace IncEnters Into Credit Agreement With Midcap Funding Iv Trust - marketscreener.com
NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives - Nasdaq
NeuroPace Secures Up to $75 Million in Debt Financing - TradingView
$75M Financing Fuels NeuroPace's Epilepsy Treatment Expansion: 5 Key Growth Initiatives Revealed - Stock Titan
Lost Money on NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
FY2028 EPS Estimates for NeuroPace Cut by Leerink Partnrs - MarketBeat
Research Analysts Set Expectations for NeuroPace Q3 Earnings - MarketBeat
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc.NPCE - FinancialContent
Cantor Fitzgerald maintains overweight rating on NeuroPace stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains overweight rating on NeuroPace stock - Investing.com
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - PR Newswire
NeuroPace, Inc. (NASDAQ:NPCE) Shares Sold by Millennium Management LLC - MarketBeat
Q2 Earnings Estimate for NeuroPace Issued By HC Wainwright - MarketBeat
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $15.50 - Defense World
Q2 Earnings Forecast for NeuroPace Issued By HC Wainwright - Defense World
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Northern Trust Corp - MarketBeat
FY2028 EPS Estimates for NeuroPace Decreased by Analyst - Defense World
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud - ACCESS Newswire
Point72 Asset Management L.P. Takes $369,000 Position in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace (NASDAQ:NPCE) Now Covered by HC Wainwright - Defense World
NeuroPace falls after setback in trial for neuromodulation system - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) Initiates Coverage with "Buy" Rating by HC Wain - GuruFocus
H.C. Wainwright sets $18 target on NeuroPace stock with Buy rating - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, ... - Eagle-Tribune
NeuroPace Inc (NPCE) Shares Gap Down to $11.75 on May 28 - GuruFocus
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial - Yahoo Finance
NeuroPace reports initial one-year outcomes from trial of RNS System - Yahoo Finance
HC Wainwright & Co. Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - Nasdaq
Analyst Expectations For NeuroPace's Future - Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright Initiates NeuroPace at Buy With $18 Price Target - marketscreener.com
Transcript : NeuroPace, Inc.Special Call - marketscreener.com
NeuroPace (NPCE) Receives Positive Initiation from H.C. Wainwrig - GuruFocus
NeuroPace (NPCE) Shares NAUTILUS Study Results on RNS System | N - GuruFocus
NeuroPace reports mixed results in epilepsy study By Investing.com - Investing.com India
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
Neuropace Inc (NPCE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.56%
0.13%
大文字化:
|
ボリューム (24 時間):